Navigation Links
Src Inhibitors in Breast Cancer Therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha .

These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers.

This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression.

They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis.

In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth.

The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

AUTHOR CONTACT: Joyce M. Slingerland University of Miami Miller School of Medicine, Miami, Florida, USA. Phone : (305) 243-7265; Fax: (305) 243-4787; E-mail: jslingerland@med.miami.edu


'"/>




Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. ACE Inhibitors For Vascular Disease Patients
5. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
6. Consensus on "Combination Therapy" for Breast Cancer
7. Breast cancer treatment to be determined by gene test
8. Breast Feeding prevents obesity later on in life
9. Breast milk is essential
10. Breast Cancer Surgery Causes Psychological problems
11. Breast cancer evidence
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has officially ... expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the dirt ... photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, LLUH, ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, ... first penis transplant in the United States . The 64-year-old patient who received the ... The transplant could restore not only a natural appearance, but also urinary and sexual ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... YORK , May 23, 2016 ... Spectrometry Market Size, Share, Development, Growth and Demand ... (Hybrid, Single and Other), by Application (Drug Discovery ... by End Users (Pharmaceuticals, Life Science and Biotechnology, ... by P&S Market Research, the global mass ...
(Date:5/23/2016)... UAE, May 23, 2016 Experts ... of Precision Medicine and the role of technology ...   The First International Conference of VPS-Penn Medicine ... distinguished patronage and presence of Sheikh Nahyan bin Mubarak Al ... in Precision Medicine, which helps provide personalized medicine and tailor-made ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology: